Regeneron (REGN) Stock Forecast & Price Target

Compare

4,760 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

REGN Analyst Ratings

Moderate Buy

17 Buy

6 Hold

1 Sell

Based on 24 analysts giving stock ratings to

Regeneron

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

REGN Stock 12 Month Forecast

Average Price Target

$730.29

▲(32.78%Upside)

Based on 24 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is $730.29 with a high forecast of $900.00 and a low forecast of $535.00. The average price target represents a 32.78% change from the last price of $550.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"489":"$489","1182":"$1,182","662.25":"$662.3","835.5":"$835.5","1008.75":"$1,008.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$900.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":730.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$730.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":535,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$535.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[489,662.25,835.5,1008.75,1182],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,534.91,562.9938461538461,591.0776923076922,619.1615384615384,647.2453846153846,675.3292307692308,703.4130769230769,731.496923076923,759.5807692307692,787.6646153846154,815.7484615384615,843.8323076923077,871.9161538461539,{"y":900,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,534.91,549.9392307692308,564.9684615384615,579.9976923076923,595.026923076923,610.0561538461538,625.0853846153846,640.1146153846154,655.1438461538461,670.1730769230769,685.2023076923076,700.2315384615384,715.2607692307693,{"y":730.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,534.91,534.916923076923,534.9238461538462,534.9307692307692,534.9376923076923,534.9446153846154,534.9515384615385,534.9584615384615,534.9653846153846,534.9723076923077,534.9792307692308,534.9861538461538,534.993076923077,{"y":535,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1054.11,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1090.13,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1181.42,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1044.02,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":841.27,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":760.24,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":710.37,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":671.12,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":697.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":616.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":589.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":490.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":534.91,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$900.00

Average Price Target$730.29

Lowest Price Target$535.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$614

Buy

11.64%

Upside

Reiterated

07/16/25

Regeneron's overall stock score reflects its strong financial performance and reasonable valuation, offset by mixed technical signals and challenges highlighted in the earnings call. The company's diverse product pipeline and strategic collaborations provide a solid foundation for future growth, but current hurdles must be addressed to improve stock performance.

Sean McCutcheonRaymond James

Raymond James

―

Hold

―

Reiterated

07/17/25

Analysts Offer Insights on Healthcare Companies: Novartis (NYSE: NVS), Regeneron (NASDAQ: REGN) and Veeva Systems (NYSE: VEEV)

Trung HuynhUBS

UBS

$560→$584

Hold

6.18%

Upside

Reiterated

07/11/25

Regeneron price target raised to $584 from $560 at UBSRegeneron price target raised to $584 from $560 at UBS

Terence FlynnMorgan Stanley

Morgan Stanley

$755→$754

Buy

37.09%

Upside

Reiterated

07/10/25

Regeneron price target lowered to $754 from $755 at Morgan StanleyRegeneron price target lowered to $754 from $755 at Morgan Stanley

Evan SeigermanBMO Capital

BMO Capital

$600

Buy

9.09%

Upside

Reiterated

07/09/25

Regeneron (REGN) Gets a Buy from BMO Capital

Mohit BansalWells Fargo

Wells Fargo

$580

Hold

5.45%

Upside

Reiterated

07/09/25

Wells Fargo Remains a Hold on Regeneron (REGN)

David RisingerLeerink Partners

Leerink Partners

$645

Buy

17.27%

Upside

Reiterated

07/07/25

Positive Outlook for Regeneron: Buy Rating Backed by FDA Approvals, Patent Extensions, and Growth Projections

Chris SchottJ.P. Morgan

J.P. Morgan

$800

Buy

45.45%

Upside

Reiterated

07/07/25

Regeneron Buy Rating: Strong Dupixent Performance and Upcoming Catalysts Offset Eylea Challenges

William PickeringBernstein

Bernstein

$896→$750

Buy

36.36%

Upside

Assigned

07/07/25

Analysts Are Bullish on These Healthcare Stocks: Sanofi (SNYNF), Regeneron (REGN)

Brian AbrahamsRBC Capital

RBC Capital

$662→$688

Hold

25.09%

Upside

Reiterated

07/07/25

Regeneron (REGN) Gets a Hold from RBC Capital

Tyler Van BurenTD Cowen

TD Cowen

$800

Buy

45.45%

Upside

Reiterated

07/03/25

TD Cowen Remains a Buy on Regeneron (REGN)

Geoff MeachamCiti

Citi

$650

Buy

18.18%

Upside

Reiterated

07/02/25

Regeneron (REGN) Receives a Buy from Citi

Jasper HellwegArgus Research

Argus Research

―

Hold

―

Downgraded

06/30/25

Regeneron downgraded to Hold from Buy at ArgusRegeneron downgraded to Hold from Buy at Argus

Tim AndersonBank of America Securities

Bank of America Securities

$535

Sell

-2.73%

Downside

Reiterated

06/06/25

Bank of America Securities Remains a Sell on Regeneron (REGN)

Akash TewariJefferies

Jefferies

$914→$804

Buy

46.18%

Upside

Reiterated

06/04/25

Regeneron: Buy Rating Backed by Promising Pipeline and Market Expansion Potential

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$614

Buy

11.64%

Upside

Reiterated

07/16/25

Sean McCutcheonRaymond James

Raymond James

―

Hold

―

Reiterated

07/17/25

Analysts Offer Insights on Healthcare Companies: Novartis (NYSE: NVS), Regeneron (NASDAQ: REGN) and Veeva Systems (NYSE: VEEV)

Trung HuynhUBS

UBS

$560→$584

Hold

6.18%

Upside

Reiterated

07/11/25

Regeneron price target raised to $584 from $560 at UBSRegeneron price target raised to $584 from $560 at UBS

Terence FlynnMorgan Stanley

Morgan Stanley

$755→$754

Buy

37.09%

Upside

Reiterated

07/10/25

Regeneron price target lowered to $754 from $755 at Morgan StanleyRegeneron price target lowered to $754 from $755 at Morgan Stanley

Evan SeigermanBMO Capital

BMO Capital

$600

Buy

9.09%

Upside

Reiterated

07/09/25

Regeneron (REGN) Gets a Buy from BMO Capital

Mohit BansalWells Fargo

Wells Fargo

$580

Hold

5.45%

Upside

Reiterated

07/09/25

Wells Fargo Remains a Hold on Regeneron (REGN)

David RisingerLeerink Partners

Leerink Partners

$645

Buy

17.27%

Upside

Reiterated

07/07/25

Positive Outlook for Regeneron: Buy Rating Backed by FDA Approvals, Patent Extensions, and Growth Projections

Chris SchottJ.P. Morgan

J.P. Morgan

$800

Buy

45.45%

Upside

Reiterated

07/07/25

Regeneron Buy Rating: Strong Dupixent Performance and Upcoming Catalysts Offset Eylea Challenges

William PickeringBernstein

Bernstein

$896→$750

Buy

36.36%

Upside

Assigned

07/07/25

Analysts Are Bullish on These Healthcare Stocks: Sanofi (SNYNF), Regeneron (REGN)

Brian AbrahamsRBC Capital

RBC Capital

$662→$688

Hold

25.09%

Upside

Reiterated

07/07/25

Regeneron (REGN) Gets a Hold from RBC Capital

Tyler Van BurenTD Cowen

TD Cowen

$800

Buy

45.45%

Upside

Reiterated

07/03/25

TD Cowen Remains a Buy on Regeneron (REGN)

Geoff MeachamCiti

Citi

$650

Buy

18.18%

Upside

Reiterated

07/02/25

Regeneron (REGN) Receives a Buy from Citi

Jasper HellwegArgus Research

Argus Research

―

Hold

―

Downgraded

06/30/25

Regeneron downgraded to Hold from Buy at ArgusRegeneron downgraded to Hold from Buy at Argus

Tim AndersonBank of America Securities

Bank of America Securities

$535

Sell

-2.73%

Downside

Reiterated

06/06/25

Bank of America Securities Remains a Sell on Regeneron (REGN)

Akash TewariJefferies

Jefferies

$914→$804

Buy

46.18%

Upside

Reiterated

06/04/25

Regeneron: Buy Rating Backed by Promising Pipeline and Market Expansion Potential

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

1 Month

xxx

Success Rate

23/41 ratings generated profit

Average Return

+1.11%

assigned a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.10% of your transactions generating a profit, with an average return of +1.11% per trade.

3 Months

xxx

Success Rate

13/23 ratings generated profit

Average Return

+1.46%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.52% of your transactions generating a profit, with an average return of +1.46% per trade.

1 Year

Christopher RaymondPiper Sandler

Success Rate

27/41 ratings generated profit

Average Return

+10.25%

assigned a buy rating 6 months ago

Copying Christopher Raymond's trades and holding each position for 1 Year would result in 65.85% of your transactions generating a profit, with an average return of +10.25% per trade.

2 Years

xxx

Success Rate

15/23 ratings generated profit

Average Return

+11.70%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 65.22% of your transactions generating a profit, with an average return of +11.70% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REGN Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, REGN has received 39 Buy Ratings, 12 Hold Ratings, and 2 Sell Ratings. REGN average Analyst price target in the past 3 months is 730.29.

Each month's total comprises the sum of three months' worth of ratings.

REGN Financial Forecast

REGN Earnings Forecast

Next quarter’s earnings estimate for REGN is $8.45 with a range of $4.25 to $9.50. The previous quarter’s EPS was $8.22. REGN beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.07% of the time in the same period. In the last calendar year REGN has Preformed in-line its overall industry.

REGN Sales Forecast

Next quarter’s sales forecast for REGN is $3.29B with a range of $3.10B to $3.45B. The previous quarter’s sales results were $3.03B. REGN beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year REGN has Preformed in-line its overall industry.

REGN Stock Forecast FAQ

What is REGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Regeneron Pharmaceuticals’s 12-month average price target is 730.29.

What is REGN’s upside potential, based on the analysts’ average price target?

Regeneron Pharmaceuticals has 32.78% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is REGN a Buy, Sell or Hold?

Regeneron Pharmaceuticals has a consensus rating of Moderate Buy which is based on 17 buy ratings, 6 hold ratings and 1 sell ratings.

What is Regeneron Pharmaceuticals’s price target?

The average price target for Regeneron Pharmaceuticals is 730.29. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $900.00 ,the lowest forecast is $535.00. The average price target represents 32.78% Increase from the current price of $550.

What do analysts say about Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of REGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Regeneron (REGN) Stock Forecast & Price Target

REGN Analyst Ratings

REGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Regeneron

REGN Analyst Recommendation Trends

REGN Financial Forecast

REGN Earnings Forecast

REGN Sales Forecast

REGN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts